Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-09-04

Clinical Trial Update: Toviaz Post Marketing Surveillance Study

View source ↗

Summary

Post-marketing surveillance study of fesoterodine (Toviaz) for overactive bladder completed; results were posted on 2015-09-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Toviaz (fesoterodine fumarate)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder | Status: COMPLETED | Results posted: 2015-09-04